Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: Primary care

Medicalwriters/Science Source

Biosimilars Are Slowly Climbing Toward Acceptance in Rheumatology

Bryn Nelson, PhD  |  June 15, 2020

As useful stand-ins for biologics targeting a range of inflammatory diseases, biosimilars have made significant inroads across Europe as less expensive alternatives. Denmark, for example, realized a cost savings of 64% after instituting a mandatory national switch from the originator infliximab to its biosimilar counterpart. In the U.S., however, a considerably smaller fraction of rheumatologists…

Filed under:Biologics/DMARDsResearch Rheum Tagged with:Arthritis & Rheumatologydrug costsinfliximab

Longer Rituximab Therapy Boosts Remission in ANCA-Associated Vasculitis

Will Boggs, MD  |  June 3, 2020

NEW YORK (Reuters Health)—Long-term rituximab use lowers the chance of relapse of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV), compared with standard maintenance therapy, according to a report from the MAINRITSAN3 randomized trial. “Physicians should consider AAV to be a long-lasting, chronic disease which requires maintenance therapy,” says Dr. Pierre Charles of Cochin Hospital, Paris…

Filed under:Drug Updates Tagged with:ANCA-Associated VasculitisRemissionrituximab

Rheumatology Biologic Expertise Valued for COVID-19 Treatment Decisions

Catherine Kolonko  |  May 18, 2020

At the Loma Linda University Medical Center, Calif., rheumatologists play a key consulting role for COVID-19 patients who may benefit from the use of biologic treatments…

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiologicscoronavirusCOVID-19cytokine storm syndromeCytokinesmacrophage activation syndrome

Some Telemedicine Barriers Are Down During COVID-19 Pandemic

Larry Beresford  |  May 15, 2020

Telerheumatology—which refers to the application of electronic communication technology to clinical encounters from a distance between rheumatologists and their patients—has the potential to extend a workforce projected to experience significant shortfalls, making it more accessible to more patients. Multiple barriers that stood in the way of taking full advantage of this promise are now down—at…

Filed under:Practice SupportTechnology Tagged with:Centers for Medicare & Medicaid Services (CMS)telemedicinetelerheumatology

Analysis of National & Local Coverage Determinations

From the College  |  April 15, 2020

The Medicare statute states that items and services provided to beneficiaries must be “reasonable and necessary” to qualify for reimbursement. Although the Medicare program determines in specific cases whether an item or service is reasonable and necessary, it also issues policies, called coverage determinations, to instruct Medicare Administrative Contractors (MACs) what to reimburse providers for….

Filed under:Billing/CodingFrom the CollegePractice Support Tagged with:Centers for Medicare & Medicaid Services (CMS)local coverage determinations (LCDs)Medicare Administrative Contractors (MACs)National Coverage Determinations (NCDs)

The Latest Advances in Sjögren’s, Scleroderma, RA, Gout & More

Jason Liebowitz, MD, FACR  |  April 15, 2020

ATLANTA—At the ACR/ARP 2019 Annual Meeting, several widely renowned experts across an array of specialty subjects provided a comprehensive and compelling review of advances in the understanding, diagnosis and treatment of a number of rheumatologic conditions. Sjögren’s Syndrome Frederick Vivino, MD, FACR, chief of rheumatology at Penn Presbyterian Medical Center and professor of clinical medicine…

Filed under:Clinical Criteria/GuidelinesConditionsGout and Crystalline ArthritisGuidanceMeeting ReportsOther Rheumatic ConditionsRheumatoid ArthritisSystemic Sclerosis Tagged with:2019 ACR/ARP Annual Meetingmacrophage activation syndrome

2 Patients on Different DMARDs Experience Different COVID-19 Disease Courses

Luis A. Marcos, MD, MPH, Saika Sharmeen, DO, Jaime Gonzalez, MD, Qingping Yao, MD, PhD, Bettina Fries, MD, & Jack Fuhrer, MD  |  April 13, 2020

In March 2020, an elderly married couple living on Long Island, N.Y., presented to our emergency department with symptoms suspicious for COVID-19 infection. The wife, a-76-year-old woman, presented with complaints of subjective fevers, minimal dry cough and headaches of one-week duration. She denied having any chills, rhinorrhea, diarrhea, abdominal pain or shortness of breath. Two…

Filed under:Conditions Tagged with:COVID-19

Do You Know Your Legal Obligations to Disabled Patients?

Kurt Ullman  |  April 13, 2020

The Americans with Disabilities Act (ADA) was passed in 1990 to protect the civil rights of people with disabilities. This law, and amendments passed in 2008, resulted in rules and regulations opening access to private settings serving the public, including doctors’ offices and medical facilities. The ADA includes a three-pronged definition of disability. If any…

Filed under:Legal UpdatesPatient Perspective Tagged with:Americans with Disabilities Act

A Collaborative Website as a Communication Model During the COVID-19 Pandemic

Sheryl Mascarenhas, MD, with Greg Stevens, BS  |  April 10, 2020

Under the onslaught of developing information on COVID-19, one health system found a way to streamline communication using a secure tool it already had access to.

Filed under:Information TechnologyPractice SupportTechnology Tagged with:COVID-19SharePoint

Tocilizumab Begins Clinical Trial for COVID-19

Michele B. Kaufman, PharmD, BCGP  |  April 7, 2020

The FDA has authorized a phase 3 clinical trial examining the safety and efficacy of tocilizumab plus standard care in patients hospitalized with COVID-19…

Filed under:Drug Updates Tagged with:coronavirusCOVID-19FDAsubcutaneous tocilizumabtocilizumabU.S. Food and Drug Administration (FDA)

  • « Previous Page
  • 1
  • …
  • 86
  • 87
  • 88
  • 89
  • 90
  • …
  • 137
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences